Good morning :)
$
₹
The Oncology Institute, Inc.

The Oncology Institute, Inc.

STLN

NASDAQ
Asset Logo

The Oncology Institute, Inc.

STLN

NASDAQ
$6.296.18% (-0.41)
$
₹
$6.296.18% (-0.41)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Care Facilities

Small Cap

With a market cap of $683.9M the stock is ranked 3016

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.76
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.29
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-6.18%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+40.09%

Earnings Growth

+70.99%

Rev. Growth

+32.28%

See Detailed Forecast

Company Profile

Company Profile

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$6.71Baseline
Analyst Target - 1 year
Target$9.4+40.09%

All values in $

202220232024202520262027$2.79$5.31$7.82Target+40.09%
2026
Current$6.71Baseline
Analyst Target - 1 year
Target$9.4+40.09%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 32.28% growth, versus a trailing 3-year CAGR of 25.81%.

2025
Current$502.72Baseline
Forecast for Dec 2026
High$669.5+33.17%
Average$665.01+32.28%
Low$659.92+31.27%

All values in $ Million

20222023202420252026252.48324.23393.41502.72Low+31.27%Average+32.28%High+33.17%
2025
Current$502.72Baseline
Forecast for Dec 2026
High$669.5+33.17%
Average$665.01+32.28%
Low$659.92+31.27%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.56Baseline
Forecast for Dec 2026
High$-0.11+80.3%
Average$-0.16+70.99%
Low$-0.21+62.4%

All values in $

20222023202420252026-0.13-0.92-0.71-0.56Low+62.4%Average+70.99%High+80.3%
2025
Current$-0.56Baseline
Forecast for Dec 2026
High$-0.11+80.3%
Average$-0.16+70.99%
Low$-0.21+62.4%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

136.5
-16.5
141.9
-7.5
147.4
-2.4
161.2
-9.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue104.40119.80136.56141.95147.44161.28
Net Income-19.58-17-16.50-7.50-2.49-9.78
Net Profit Margin-18.75%-14.19%-12.08%-5.28%-1.69%-6.06%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Care Facilities

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
The Oncology Institute, Inc. -0.76-
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare STLN with any stock or ETF
Compare STLN with any stock or ETF
Comparing from
STLN
ABT
DHR
Loading...

Frequently asked questions

  1. The Oncology Institute, Inc. (STLN) share price today is $6.29 as of October 27, 2026 at 1:29 AM IST. The stock touched a day high of $6.80 and a day low of $6.20.

  2. The Oncology Institute, Inc. stock trades on NASDAQ under the ticker symbol STLN.

  3. The Oncology Institute, Inc.'s market capitalization is $683.85M as of October 27, 2026 at 1:29 AM IST.

  4. The Oncology Institute, Inc.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. The Oncology Institute, Inc.'s price-to-book (P/B) ratio is 0.76 as of October 26, 2026.

  6. Yes, You can buy The Oncology Institute, Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy The Oncology Institute, Inc. shares in three steps: 1. Search The Oncology Institute, Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since The Oncology Institute, Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in The Oncology Institute, Inc. (STLN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.5885 shares at the current price of $6.29.

Loading...